Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference

Rhea-AI Summary

Quanterix (NASDAQ: QTRX) announced the participation of its CEO Masoud Toloue and CFO Vandana Sriram at the 45th Annual Goldman Sachs Global Healthcare Conference. The company specializes in ultrasensitive biomarker detection to advance scientific discovery. The fireside chat presentation is scheduled for June 12, 2024, at 2:40 p.m. EST and will be webcast live. Replays will be available for a time post-conference. For more details, visit the Investor Relations section on Quanterix's website.

Positive

• CEO and CFO participation at a significant industry event may boost investor confidence.
• Webcast availability ensures accessibility and transparency for shareholders.
• Involvement in the Goldman Sachs conference highlights Quanterix's relevance in the healthcare sector.

Negative

• The press release lacks new financial or clinical data.
• No immediate information on revenue growth or profitability, which might concern investors.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general public via webcast.

Webcast Information

To access the live webcast of Quanterix’s fireside chat presentation at the conference, please visit this link.

Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of the company’s website.

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605682576/en/

Media Contact:

PAN Communications

Maya Nimnicht

510-334-6273

quanterix@pancomm.com

Investor Relations Contact:

Quanterix

Francis Pruell

(508)-789-1725

ir@quanterix.com

Source: Quanterix Corporation

FAQ

When will Quanterix present at the Goldman Sachs Global Healthcare Conference?

Quanterix will present on June 12, 2024, at 2:40 p.m. EST.

Who will represent Quanterix at the Goldman Sachs Healthcare Conference?

CEO Masoud Toloue and CFO Vandana Sriram will speak at the conference.

How can I access the Quanterix presentation at the Goldman Sachs conference?

The presentation will be webcast live and available through the Investor Relations section on Quanterix's website.

What is the significance of Quanterix's participation in the Goldman Sachs conference?

Participation can enhance company visibility and investor confidence in Quanterix's market position.